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A B S T R A C T
Objectives: To report health-state utility values measured using the
ﬁve-level EuroQol ﬁve-dimensional questionnaire (EQ-5D-5L) in a large
sample of patients with end-stage renal disease and to explore how
these values vary in relation to patient characteristics and treatment
factors. Methods: As part of the prospective observational study
entitled “Access to Transplantation and Transplant Outcome Meas-
ures,” we captured information on patient characteristics and treat-
ment factors in a cohort of incident kidney transplant recipients and a
cohort of prevalent patients on the transplant waiting list in the United
Kingdom. We assessed patients’ health status using the EQ-5D-5L and
conducted multivariable regression analyses of index scores. Results:
EQ-5D-5L responses were available for 512 transplant recipients and
1704 waiting-list patients. Mean index scores were higher in transplant
recipients at 6 months after transplant surgery (0.83) compared with
patients on the waiting list (0.77). In combined regression analyses, a
primary renal diagnosis of diabetes was associated with the largest
decrement in utility scores. When separate regression models were
ﬁtted to each cohort, female gender and Asian ethnicity were asso-
ciated with lower utility scores among waiting-list patients but not
among transplant recipients. Among waiting-list patients, longer time
spent on dialysis was also associated with poorer utility scores. When
comorbidities were included, the presence of mental illness resulted in
a utility decrement of 0.12 in both cohorts. Conclusions: This study
provides new insights into variations in health-state utility values
from a single source that can be used to inform cost-effectiveness
evaluations in patients with end-stage renal disease.
Keywords: end-stage renal disease, EQ-5D-5L, health-state utility
values, multivariable regression.
& 2017 The Authors. Published by Elsevier Inc. on behalf of Interna-
tional Society for Pharmacoeconomics and Outcomes Research
(ISPOR). All rights reserved. This is an open access article under the
CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Estimates of health-state utility values are required to undertake
cost-effectiveness evaluations in which quality-adjusted life-
years are the outcome of interest. Utility estimates can be
captured using patient-reported questionnaires as part of a
clinical trial or observational study, but in the absence of primary
data, estimates are often sourced from published literature.
End-stage renal disease (ESRD) is a chronic condition that has
been shown to impact patients’ health status. Numerous studies
have been conducted to measure utility values among patients
receiving renal replacement therapy. Meta-analyses of published
studies suggest that higher utility values are generally observed
among patients who receive kidney transplants in comparison
with those on dialysis [1,2]. Pooling results across studies can be
an appealing approach to obtain a summary estimate (weighted
average with associated uncertainty) of a utility value for each
health state of interest that can be used to quality-adjust survival
in a cost-effectiveness model. However, caution is required when
undertaking meta-analyses of health-state utility values because
there is often considerable variability in utility scores as a result
of using different valuation methods across studies [3]. A further
limitation of pooled utility estimates is that they may not be able
to take into account heterogeneity of patient characteristics and
treatment or measurement factors that could explain variations
in utility scores for a given condition. Individual utility studies
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often have small sample sizes and each study may collect only a
limited number of covariates that are not comparable across
studies or not always relevant to a speciﬁc decision problem or
patient population.
The Access to Transplantation and Transplant Outcome Meas-
ures (ATTOM) study is a prospective observational study that
involved collection of a wide range of data on patient characteristics,
treatment factors and health outcomes from all 72 renal units in the
United Kingdom. As part of this study, we recruited a cohort of
incident kidney transplant and simultaneous (combined) pancreas
and kidney (SPK) transplant recipients as well as a cohort of prevalent
waiting-list patients selected as controls for transplanted patients [4].
Collection of health-state utility values as part of the ATTOM study
has facilitated the following objectives of the present analysis:
1. To report health-state utility values for a large sample of
patients with ESRD using the ﬁve-level version of the EuroQol
ﬁve-dimensional questionnaire (EQ-5D-5L).
2. To conduct multivariable regression analyses to understand
patient and treatment factors associated with variations in
health-state utility values among kidney transplant recipients
and waiting-list patients that can then be used to inform quality
adjustment of life-years in cost-effectiveness evaluations.
Cost-effectiveness analyses involving patients with ESRD have
been undertaken to address a wide range of decision problems,
including comparisons of dialysis versus transplantation [5–9],
alternative dialysis modalities or initiation strategies [10–12],
alternative approaches to kidney allocation [13], and different
immunosuppressive therapies after transplantation [14–16]. Given
that there may be considerable variation among cost-effectiveness
analyses in terms of the target population or the data available to
researchers on patient characteristics, we present utility values for
a range of potential modeling needs. We demonstrate that with
access to more detailed information, we can gain greater insight
into the extent of variation in health-state utility values among
patients with ESRD. To our knowledge, this is the largest study to
date to report health-state utility values based on EQ-5D-5L
responses collected in both kidney transplant recipients and
waiting-list patients in the United Kingdom.
Methods
The EQ-5D is a widely used generic instrument for describing and
valuing health in terms of ﬁve dimensions: mobility, self-care,
usual activities, pain/discomfort, and anxiety/depression. The
original version of the EQ-5D has three levels of response
categories for each dimension, ranging from no problems to
extreme problems [17]. More recently, a ﬁve-level version of the
questionnaire was developed in an attempt to improve the
instrument’s sensitivity and to reduce ceiling effects [18].
Patients aged 18 to 75 years who received a kidney or SPK
transplant in the United Kingdom between November 1, 2011,
and September 30, 2013, were approached for recruitment into
the ATTOM study. Patients were asked to complete the EQ-5D-5L
at recruitment (within 90 days of transplant). Patients who were
enrolled during the ﬁrst 6 months of the ATTOM study were
approached at approximately 6 months post-transplant to com-
plete the EQ-5D-5L again. It was not possible to capture EQ-5D-5L
responses at 6 months in all transplant recipients because study
nurses were only available on site to administer questionnaires
for a total period of 12 months. The present analysis focuses only
on the EQ-5D-5L data collected at 6 months because this is likely
to be a more stable reﬂection of post-transplant health status
than data collected within 90 days of transplant when patients
may still be recovering from surgery.
Patients on the kidney transplant waiting list were selected as
matched controls for every incident transplant recipient on the
basis of the following criteria: transplant center, age (within 5
years), time on the waiting list, type of transplant (kidney only or
SPK), diabetes status (as a primary renal diagnosis), and dialysis
status (at the time of listing) [4]. The selection of patients on the
waiting list as matched controls in the ATTOM study was
designed for the purpose of studying survival as an outcome
rather than speciﬁcally for the measurement of health status.
Because patients were not necessarily matched on the basis of
health status, this article will refer to the two cohorts as trans-
plant recipients and waiting-list patients (rather than matched
controls). For waiting-list patients, EQ-5D-5L responses were
captured within 90 days of recruitment. Waiting-list patients
were prevalent patients who had been receiving dialysis for
varying periods of time. Therefore, the EQ-5D-5L assessment at
recruitment in these patients did not represent the start of
dialysis as a treatment modality. Recruitment of a prevalent
cohort of waiting-list patients facilitates an analysis of health-
state utility values in relation to the length of time that patients
had been receiving dialysis.
Questionnaire responses were converted to index scores using
the preliminary EQ-5D-5L value set for England, which can be
accessed via a link on the EuroQol Web site (www.euroqol.org) [19].
We undertook ordinary least squares (OLS) regression with robust
standard errors to explore the inﬂuence of transplant versus
waiting-list status with and without the addition of age, gender,
ethnicity, and diabetes as a primary renal diagnosis and summar-
ized model ﬁt by reporting Akaike information criterion values. To
investigate the effect of additional patient characteristics collected
in the ATTOM study on health-state utility values, we also ﬁtted
separate multivariable regression models for transplant recipients
and waiting-list patients. This allowed us to explore the effect of
donor type (deceased versus living donor) and kidney alone versus
SPK transplant among transplant recipients and time on dialysis
among patients on the waiting list. For both patient populations,
we also considered smoking status and comorbidities that occurred
in at least 5% of patients. Final multivariable models were based on
covariates that were signiﬁcant at a P-value cut-off point of 0.10.
Comorbidity information was missing for less than 1% of
transplant recipients and waiting-list patients and these observa-
tions were omitted from the separate multivariable regression
analyses. Among patients on the waiting list, approximately 30%
had missing information about time on dialysis and therefore we
performedmultiple imputation creating 10 imputed data sets using
ordered logistic regression before ﬁtting the multivariable model.
All analyses were conducted in Stata version 14 (StataCorp,
College Station, TX).
Results
Tables 1 and 2 summarize the characteristics of all patients who
were recruited into the ATTOM study in each cohort in compar-
ison with the characteristics of the subset of patients who
completed the EQ-5D-5L in each cohort. For waiting-list patients,
EQ-5D-5L responses were available in 87% of the cohort and the
characteristics of the patients who completed the questionnaire
were broadly consistent with those of the overall population. For
transplant recipients, EQ-5D-5L responses at 6 months post-
transplant were available only in 23% of the cohort, with some
under-representation from patients of nonwhite ethnicity, SPK
transplants, and patients who experienced graft failure or death.
The proportion of transplant recipients and waiting-list
patients reporting each level of problems for each dimension
on the EQ-5D-5L is shown in Figure 1. The largest differences
between transplant recipients and waiting-list patients are seen
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in the proportion of patients who indicated level 1 versus level 2
in the dimensions for mobility and usual activities.
Table 3 shows the inﬂuence of various combinations of
predictor variables on health-state utility values taking waiting-
list patients as the constant. Transplant recipients have signiﬁ-
cantly higher mean utility scores than waiting-list patients. The
largest utility decrement across all models is associated with
diabetes.
Tables 4 and 5 present multivariable regression models for
transplant recipients and waiting-list patients, respectively. For
both models, the presence of mental illness as a comorbidity was
associated with the largest utility decrement. Running separate
regression models for each patient group not only allows us to
explore the effect of treatment-speciﬁc covariates such as donor
type for transplant recipients or the length of time on dialysis for
waiting-list patients, but also suggests that the magnitude of the
effect of covariates such as diabetes may differ between patient
groups. In addition, controlling for other variables, we found that
age was no longer a signiﬁcant predictor of health-state utility
values in either of the ﬁnal regression models. Variance-
covariance matrices for all regression models are available in
Supplemental Materials found at http://dx.doi.org/10.1016/j.jval.
2017.01.011.
Discussion
Estimates of health-state utility values to inform cost-
effectiveness evaluations are often sourced from the published
literature. As the volume of published utility estimates for many
disease areas continues to grow, analysts undertaking cost-
effectiveness evaluations increasingly need to justify their
Table 1 – Summary of characteristics for transplant recipients who completed an EQ-5D-5L assessment at 6 mo
compared with all transplant recipients.
Characteristic Transplant recipients with
EQ-5D-5L assessment
(total ¼ 512)
All transplant
recipients
(total ¼ 2250)
P value*
n % n %
Age (y)
18–29 41 8.0 233 10.4 0.157
30–39 62 12.1 322 14.3
40–49 128 25.0 550 24.4
50–59 140 27.3 591 26.3
460 141 27.5 554 24.6
Gender
Male 307 60.0 1413 62.8 0.184
Female 205 40.0 837 37.2
Ethnicity
White 452 88.3 1857 82.5 0.006
Asian 28 5.5 209 9.3
Black 24 4.7 140 6.2
Other 8 1.6 44 2.0
Diabetes (primary renal diagnosis) 60 11.7 322 14.3 0.095
Transplanted organ
Kidney only 489 95.5 2099 93.3 0.046
Combined kidney and pancreas 23 4.5 151 6.7
Donor type
Deceased donor 320 62.5 1439 64.0 0.480
Living donor 192 37.5 811 36.0
Comorbidities
Ischemic heart disease 48 9.4 193 8.6 0.822
Respiratory disease 47 9.2 174 7.7 0.353
Malignancy 45 8.8 144 6.4 0.068
Mental illness 28 5.5 133 5.9 0.698
Smoking status
Nonsmoker 277 54.1 1207 53.6 0.128
Current smoker 43 8.4 239 10.6
Ex-smoker 151 29.5 214 26.2
Unknown 41 8.0 590 9.5
Graft failure at time of EQ-5D-5L assessment† 2 0.4 58 2.6 o0.001
Graft failure at any time during follow-up 15 2.9 112 5.0 0.033
Graft failure status missing 2 0.4 7 0.3
Patient death at time of EQ-5D-5L assessment† 0 0.0 23 1.0 o0.001
Patient death at any time during follow-up 8 1.6 67 3.0 0.013
Patient death status missing 58 11.3 275 12.2
EQ-5D-5L, ﬁve-level EuroQol ﬁve-dimensional questionnaire.
* Chi-square goodness of ﬁt.
† For patients with no EQ-5D assessment, this refers to status at 6 mo after transplant.
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approach for selecting which values to use as inputs in their
models [20,21]. One strategy is to select a single study from the
published literature that most closely reﬂects the patient pop-
ulation (inclusion/exclusion criteria), disease stage, and health
states deﬁned in the model. In contrast, if multiple studies
estimating health-state utility values for the same disease state
have been published, another strategy is to pool estimates across
studies using meta-analytic techniques. In some cases, neither of
these strategies is entirely satisfactory; a single study may not
report utility estimates for the full range of health states of
interest in the cost-effectiveness model but meta-analysis may
be unsuitable because of the high levels of heterogeneity arising
from differences in the methods used to value health states
[3,22]. This has given rise to the practice of selecting health-state
utility estimates from separate studies to inform the different
comparator arms in a cost-effectiveness model, to distinguish
between patient subgroups, or to capture decrements in utility
because of adverse events and comorbidities. Drawing on data
from disparate sources to inform the same cost-effectiveness
model can potentially lead to inconsistent or implausible values
and raise additional questions about how utility values should be
combined [22,23].
Published systematic reviews have identiﬁed a large number
of studies capturing health-state utility values among patients
with ESRD. In studies by Liem et al. [1] and Wyld et al. [2], health-
state utility values were more extensively studied in dialysis
patients than in transplant patients and only a minority of
studies evaluated health status in both groups of patients at
the same time. In the ATTOM study, we recruited incident kidney
and SPK transplant recipients and also identiﬁed a cohort of
prevalent patients on the transplant waiting list. In addition to
administering the EQ-5D-5L, we collected data on a range of
patient characteristics and treatment factors to allow us to
explore their effects on utility scores. Our analysis conﬁrms
previous ﬁndings that transplant recipients have higher utility
scores than dialysis patients. The mean utility score at 6 months
for transplant recipients in our study (0.83) was similar to the
values reported in meta-analyses by Liem et al. (0.81) and Wyld
et al. (0.82). The mean utility score for patients on the transplant
waiting list in our study was 0.77, higher than the mean values
reported among dialysis patients by Liem et al. (0.56 for hemo-
dialysis, 0.68 for peritoneal dialysis patients) and Wyld et al.
(0.71). In our analysis, we also ﬁtted separate regression models
for transplant recipients and waiting-list patients. It may seem
Table 2 – Summary of characteristics for waiting-list patients who completed an EQ-5D-5L assessment at
recruitment compared with all waiting-list patients.
Characteristic Waiting-list patients with EQ-5D-5L
assessment (total ¼ 1704)
All waiting-list patients
(total ¼ 1959)
P value*
n % n %
Age (y)
18–29 137 8.0 162 8.3 0.927
30–39 224 13.2 260 13.3
40–49 412 24.2 485 24.8
50–59 481 28.2 551 28.1
460 450 26.4 501 25.6
Gender
Male 984 57.8 1135 57.9 0.898
Female 720 42.3 824 42.1
Ethnicity
White 1299 76.2 1463 74.7 0.503
Asian 192 11.3 242 12.4
Black 178 10.5 213 10.9
Other 35 2.1 41 2.1
Diabetes (primary renal diagnosis) 195 11.4 238 12.2 0.955
Time on dialysis
Predialysis 98 5.8 107 5.5 o0.001†
o1 y 224 13.2 224 11.4
1–3 y 389 22.8 389 19.9
43 y 457 26.8 457 23.3
Missing 536 31.5 782 39.9
Comorbidities
Ischemic heart disease 166 9.7 179 9.1 0.627
Respiratory disease 119 7.0 138 7.0 0.977
Malignancy 122 7.2 135 6.9 0.872
Mental illness 125 7.3 141 7.2 0.973
Smoking status
Nonsmoker 854 50.1 977 49.9 0.333
Current smoker 238 14.0 262 13.4
Ex-smoker 387 22.7 432 22.0
Unknown 225 13.2 288 14.7
EQ-5D-5L, ﬁve-level EuroQol ﬁve-dimensional questionnaire.
* Chi-square goodness of ﬁt.
† If missing category is excluded, P ¼ 0.870.
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counterintuitive at ﬁrst glance that the constant for waiting-list
patients was higher than the constant for transplant recipients.
The higher constant in the model for the waiting-list population
reﬂects the health status of the 6% of patients who had not yet
commenced dialysis. In the ATTOM study, the waiting-list pop-
ulation consisted of prevalent patients who had been receiving
dialysis for varying periods of time, thus providing an opportu-
nity to quantify decrements in health status in relation to time
spent on dialysis.
We made a number of other notable observations based on
the results of our regression analyses. First, diabetes was con-
sistently associated with lower health-state utility values. Other
studies have reported a similar ﬁnding, but of varying magnitude.
Wyld et al. [2] reported a utility decrement of 0.10 for patients
with diabetes. A single-center study of transplant recipients in
the United States reported a utility decrement of 0.05 for patients
with diabetes [24], and a study of patients receiving peritoneal
dialysis in Thailand reported a decrement of 0.24 [25]. Second,
female gender and Asian ethnicity were associated with margin-
ally lower utility scores in the combined regression analysis for
all patients, but when we ran separate analyses for each cohort,
these covariates were retained only in the model for waiting-list
patients. We were not able to investigate the reasons for these
ﬁndings in the present analysis, but they warrant further con-
sideration of the impact this could have on expected health gains
for different patient groups as a result of transplantation. Third,
in the separate multivariable regression models for transplant
recipients and waiting-list patients, the analyses showed that
when we were able to control for other factors affecting health
status such as comorbidities and length of time on dialysis, age
no longer had any additional explanatory effect on index scores.
The systematic review by Wyld et al. [2] attempted to explore the
effect of age on utility estimates. When data were available, the
authors found that mean patient age did not signiﬁcantly
inﬂuence utility; however they, stated that they were not able
to further investigate the effect of age because of incomplete
reporting and use of mean age rather than patient-level data.
Primary collection of data on health-state utility values can be
a time-consuming and resource-intensive exercise, making the
published literature a valuable source of estimates to inform
cost-effectiveness evaluations. Looking across some of the cost-
effectiveness analyses in patients with ESRD published in the last
10 years [7–9,12,15,16], there is still a concentrated reliance on
utility estimates from a small number of studies published before
1999, all with sample sizes of fewer than 200 patients [26–28]. For
cost-effectiveness evaluations that adopt a cohort modeling
approach, it may be sufﬁcient to source mean utility estimates
by treatment modality. However, with increasing use of patient-
level modeling, it may also be desirable to have access to utility
estimates that capture variability in outcomes across the patient
population. The ﬁnal multivariable regression models that were
ﬁtted separately in the transplant recipient and waiting-list
populations in our analysis provide insight into how health-
state utility values vary by a range of patient characteristics.
One of the strengths of the ATTOM study is the ability to
explore the effects of a wide range of covariates on health status
using patient-level data, but there may be other important con-
founders that we did not capture and were not able to control for
in our analyses. Another important limitation of the study design
with respect to this analysis is that the process of selecting
patients as matched controls from the transplant waiting list
was not speciﬁcally done on the basis of health status but rather
to inform an analysis of survival. For this reason, in addition to
reporting combined regression analyses of EQ-5D-5L responses for
transplant recipients and waiting-list patients, we explored the
effect of treatment-speciﬁc covariates in separate regression mod-
els for each cohort. Although sample sizes for each cohort in this
study were larger than those in many previous studies that have
estimated health-state utility values in patients with ESRD, the
number of EQ-5D-5L responses that we were able to collect at
6 months in the transplant cohort was lower than planned. We
explored the representativeness of the subset of patients with
EQ-5D-5L responses in relation to the overall recruited population
of transplant recipients. Patients with EQ-5D-5L responses were
Fig. 1 – Health proﬁle showing the proportion of patients reporting each level of problems for each dimension on the EQ-5D-5L
questionnaire for transplant recipients (TX) and waiting-list patients (WL). EQ-5D-5L, ﬁve-level EuroQol ﬁve-dimensional
questionnaire.
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Table 3 – Inﬂuence of predictor variables on health-state utility values for waiting-list patients (constant) and
transplant recipients (n ¼ 2216).
Model Coefﬁcient Robust
standard error
P value 95% CI AIC
Model 1: transplant vs. waiting list
Waiting list (constant) 0.773 0.005 o0.001 0.762 to 0.783 408.9
Transplant þ0.054 0.011 o0.001 0.032 to 0.075
Model 2: transplant vs. waiting list, age
Waiting list, aged 18–29 y (constant) 0.814 0.015 o0.001 0.784 to 0.844 413.4
Age (y)
30–39 0.046 0.019 0.015 0.084 to 0.009
40–49 0.049 0.018 0.008 0.084 to 0.013
50–59 0.057 0.018 0.001 0.092 to 0.022
460 0.027 0.017 0.123 0.061 to 0.007
Transplant þ0.053 0.011 o0.001 0.032 to 0.075
Model 3: transplant vs. waiting list, gender
Waiting list, male (constant) 0.787 0.006 o0.001 0.775 to 0.800 419.6
Female 0.034 0.010 o0.001 0.052 to 0.015
Transplant þ0.053 0.011 o0.001 0.031 to 0.074
Model 4: transplant vs. waiting list, diabetes
Waiting list, nondiabetic (constant) 0.782 0.006 o0.001 0.771 to 0.793 439.4
Diabetic 0.083 0.016 o0.001 0.115 to 0.052
Transplant þ0.054 0.011 o0.001 0.033 to 0.075
Model 5: transplant vs. waiting list, age and gender
Waiting list, male aged 18–29 y (constant) 0.829 0.016 o0.001 0.798 to 0.860 424.2
Age (y)
30–39 0.047 0.019 0.014 0.084 to 0.010
40–49 0.048 0.018 0.008 0.083 to 0.013
50–59 0.058 0.018 0.001 0.093 to 0.023
460 0.029 0.017 0.100 0.063 to 0.006
Female 0.034 0.009 o0.001 0.052 to 0.015
Transplant þ0.053 0.011 o0.001 0.031 to 0.074
Model 6: transplant vs. waiting list, age, diabetes
Waiting list, nondiabetic aged 18–29 y (constant) 0.816 0.015 o0.001 0.785 to 0.846 442.1
Age (y)
30–39 0.036 0.019 0.060 0.073 to 0.002
40–49 0.040 0.018 0.028 0.076 to 0.004
50–59 0.050 0.018 0.005 0.085 to 0.015
460 0.019 0.017 0.273 0.053 to 0.015
Diabetic 0.081 0.016 o0.001 0.113 to 0.050
Transplant þ0.054 0.011 o0.001 0.032 to 0.075
Model 7: transplant vs. waiting list, age, gender, diabetes
Waiting list, male nondiabetic aged 18–29 y (constant) 0.830 0.016 o0.001 0.800 to 0.861 452.6
Age (y)
30–39 0.036 0.019 0.055 0.073 to 0.001
40–49 0.039 0.018 0.029 0.075 to 0.004
50–59 0.051 0.018 0.004 0.086 to 0.017
460 0.021 0.017 0.233 0.055 to 0.013
Diabetic 0.081 0.016 o0.001 0.112 to 0.049
Female 0.033 0.009 o0.001 0.052 to 0.015
Transplant þ0.053 0.011 o0.001 0.032 to 0.074
continued on next page
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representative in terms of age and comorbidities, but patients with
poorer outcomes (graft failure and death) were under-represented.
Nevertheless, because the rates of graft failure and patient death in
the transplant cohort at 6 months were low, this is unlikely to have
much of an impact on the estimates of mean index scores.
Similarly, we explored the representativeness of waiting-list
patients with EQ-5D-5L responses in comparison with the overall
recruited population of waiting-list patients and did not ﬁnd any
signiﬁcant differences in patient characteristics. In particular, we
did not ﬁnd any evidence to suggest that patients with poorer
health status who had been receiving dialysis for longer periods of
time were under-represented in our analysis of EQ-5D-5L
responses. In theory, it may be preferable to explore the relation-
ship between health status and treatment factors such as time on
dialysis using a longitudinal study design. The potential advan-
tages of a longitudinal design need to be balanced with other
considerations such as the time and cost associated with data
collection as well as the likelihood of loss to follow-up that could
lead to bias.
In the present analysis, we have restricted our approach to the
use of OLS regression. Although several regression modeling
approaches have been proposed in the literature to deal with the
bounded and skewed nature of health-state utility data [29–32],
we believe that OLS regression with robust standard errors is
justiﬁed in this case because the primary objective was to estimate
mean utility scores and sample sizes were relatively large. None-
theless, there are a number of other analytic approaches that could
be applied to our data set to facilitate a more comprehensive
comparison of different methods in future research.
Conclusions
When conducting cost-effectiveness evaluations of patients with
ESRD, careful consideration should be given to the treatment
strategies being compared and the selection of the most appro-
priate utility values that reﬂect the characteristics of the patient
populations of interest. The present study provides new insights
into variations in health-state utility values from a single source
that can be used to inform such evaluations in the future.
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Table 3 – continued
Model Coefﬁcient Robust
standard error
P value 95% CI AIC
Model 8: transplant vs. waiting list, age, gender, diabetes, ethnicity
Waiting list, male nondiabetic, non-Asian aged 18–29 y
(constant)
0.837 0.016 o0.001 0.807 to 0.868 457.1
Age (y)
30–39 0.038 0.019 0.045 0.075 to 0.001
40–49 0.043 0.018 0.018 0.078 to 0.007
50–59 0.054 0.018 0.002 0.089 to 0.020
460 0.025 0.017 0.152 0.059 to 0.009
Female 0.033 0.009 o0.001 0.051 to 0.015
Diabetic 0.078 0.016 o0.001 0.110 to 0.046
Asian ethnicity 0.040 0.018 0.024 0.074 to 0.005
Transplant þ0.051 0.011 o0.001 0.029 to 0.072
AIC, Akaike information criterion; CI, conﬁdence interval.
Table 4 – Transplant recipient multivariable regression model for EQ-5D-5L index scores (n ¼ 510).
Model Coefﬁcient Robust standard error P value 95% CI
Constant 0.860 0.013 o0.001 0.834 to 0.885
Primary renal diagnosis
Other Reference
Diabetes 0.103 0.036 0.004 0.173 to 0.032
Donor
Deceased Reference
Living 0.040 0.018 0.03 0.004 to 0.075
Comorbidities
Mental illness 0.121 0.045 0.008 0.210 to 0.032
Ischemic heart disease 0.093 0.048 0.052 0.187 to 0.001
Smoking status
Nonsmoker/unknown status Reference
Current smoker 0.064 0.038 0.095 0.139 to 0.011
Ex-smoker 0.048 0.021 0.023 0.089 to 0.007
CI, conﬁdence interval; EQ-5D-5L, ﬁve-level EuroQol ﬁve-dimensional questionnaire.
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